title: Vaccination against Staphylococcus aureus mastitis in two Swedish dairy herds.
abstract: BACKGROUND
  Staphylococcus aureus is a common udder pathogen in dairy cows, and may cause severe mastitis problems in some herds. In herds where normal control measures are not successful, vaccination might be an additional tool to use if sufficiently efficient. The aim of the present study was to evaluate the efficacy of a commercially available vaccine (Startvac(®), Hipra, Spain) in two commercial Swedish dairy herds where the control programs for S. aureus mastitis had been unsuccessful. Within each herd cows were randomly assigned to vaccine or control groups, and effects on udder health and milk production during 120 days after calving, and survival during the following lactation were evaluated.
  
  
  RESULTS
  A field study was performed in two high producing Swedish herds having approximately 600 (herd A) and 200 (herd B) cows. During 12 months, cows with odd numbers were vaccinated three times around calving according to label protocol, while cows with even numbers constituted the not vaccinated control group. Quarter milk samples for bacteriological culturing were collected from all cases of clinical and subclinical mastitis. The outcome was evaluated during 120 days after calving using data on SCC and daily milk yield at monthly milk recordings, and incidence of mastitis due to S. aureus, coagulase-negative staphylococci, streptococci and coliforms. Cow survival throughout lactation was also studied. In herd A, 239 and 240 cows were included in the vaccinated and control groups, respectively. Corresponding numbers for herd B was 126 and 151 cows. Significant differences between vaccinated and control groups were not found in any of the parameters investigated.
  
  
  CONCLUSIONS
  Vaccination with a commercial polyvalent vaccine did not have any beneficial effects on udder health, milk production or survival in two commercial dairy herds with mastitis problems due to S. aureus.
authors.affiliation: Växa Sverige, SE-104 25, Stockholm, Sweden. hakan.landin@vxa.se.
authors.forename: Håkan
authors.initials: H
authors.lastname: Landin
authors.affiliation: Växa Sverige, SE-104 25, Stockholm, Sweden. marie.mork@vxa.se.
authors.forename: Marie Jansson
authors.initials: MJ
authors.lastname: Mörk
authors.affiliation: Evidensia Djurkliniken Näset, SE-236 32, Höllviken, Sweden. maria.larsson@evidensia.se.
authors.forename: Maria
authors.initials: M
authors.lastname: Larsson
authors.affiliation: Department of Animal Health and Antimicrobial Strategies, National Veterinary Institute (SVA), SE-75189, Uppsala, Sweden. karin.persson-waller@sva.se.|Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden. karin.persson-waller@sva.se.
authors.forename: Karin Persson
authors.initials: KP
authors.lastname: Waller
mesh_terms: D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000382:microbiology / Q000517:prevention & control*; D003612:Dairying; D005260:Female; D007774:Lactation; D008136:Longevity; D008321:Mammary Glands, Animal / Q000502:physiology / Q000503:physiopathology; D008414:Mastitis, Bovine / Q000382:microbiology / Q000517:prevention & control*; D008892:Milk / Q000378:metabolism; D013203:Staphylococcal Infections / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D013209:Staphylococcal Vaccines / Q000008:administration & dosage*; D013211:Staphylococcus aureus / Q000276:immunology*; D013548:Sweden; D014611:Vaccination / Q000662:veterinary*
chemical_list: D013209:Staphylococcal Vaccines